ClinicalTrials.gg
Not yet recruitingNCT05967884Updated Aug 1, 2023

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

A Phase 2 interventional study of Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab in Breast Cancer, sponsored by Ottawa Hospital Research Institute. Not yet recruiting at 2 sites in Canada. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Ottawa Hospital Research Institute · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.

Planned enrollment
35th of 40
20 · median 121
Started
2023
with 2 others
Phase 2
7 of 44
1 open now
Registered
43rd of 44
by date

Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 35th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, or all of them as a file.
02

Study summary

This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor positive (ER+) breast cancer.

Read the detailed description

This is a phase II, open-label, randomized window of opportunity trial evaluating the immunologic effects within the tumour, microenvironment, and host blood of patients treated with either

  • Arm A: Cemiplimab (n=10)
  • Arm B: Cemiplimab + Dupilumab (n=10) administered prior to surgery. Randomization will be at 1:1 ratio in patients newly diagnosed with primary operable ER+* HER2- invasive breast cancer awaiting surgery in the next 4-6 weeks who are not planned for neoadjuvant therapy.

Primary Hypothesis: In ER+ breast cancer, blockade of IL-4 signalling using dupilumab enhances anti-tumor immunity (through reduced Th2 skewing) when used in combination with PD-1 inhibitors (Cemiplimab) compared to PD-1 inhibition alone in ER+ breast cancer

Primary Objective:

  • To determine whether addition of dupilumab to cemiplimab reduces TH2 skewing of the tumor, tumor microenvironment (TME) and blood in patients with ER+ breast cancer

Secondary Objectives:

  • To evaluate dynamic changes in immune cell populations as measured by in situ proteomics
  • To characterize the safety of a short-term duration of the combination of dupilumab with cemiplimab in patients with ER+ breast cancer awaiting surgery

Exploratory Objective:

  • To test the effect of tumor PD-1 gene expression and its effect on the immune response in treated and untreated patients

This is a window of opportunity trial which will require administration of cemiplimab or combination of cemiplimab + dupilumab prior to surgery. Surgery will be a minimum of 96 hours to 2 weeks after the cemiplimab. Patient follow-up after surgery will be for a period of 30 days post-surgery.

Target: 20 patients (10 in Arm A and 10 in Arm B). Accounting for screen failures and withdrawals (20%), 24 patients will be accrued.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Window of Opportunity Clinical Trials
  • cemiplimab
  • dupilumab
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients with newly diagnosed confirmed primary invasive breast cancer currently not undergoing any treatment while awaiting surgery.
  2. Invasive ductal or lobular carcinoma, invasive carcinoma Not Otherwise Specified (NOS)
  3. ER+ breast cancer (1-10%*) of any size. ER positive tumor defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines.
  4. The participant is eligible for surgery within the next 4-6 weeks.
  5. /neu must be negative by immunohistochemistry (IHC) defined as IHC 0 or 1+ or fluorescence in situ hybridization (FISH) or other ISH methods with a ratio of \< 2 according to current ASCO (American Society of Clinical Oncology)/CAP guidelines.
  6. (ECOG) performance status 0 to 2.
  7. Age ≥18 years.
  8. The participant (or legally acceptable representative if applicable) is able to provide written for the study.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected breast cancer metastasized to distant organ (lung, liver, bone, brain, abdomen)
  2. Prior therapy with any chemotherapy or endocrine for breast cancer or other cancers within last 3 months
  3. Pre-dominant histology other than invasive ductal or lobular carcinoma or invasive carcinoma NOS.
  4. Patients with an active infection or an \< 1.5 x 10\^9/L.
  1. Patients with pre-existing renal impairment, calculated by Chronic Kidney Disease Epidemiology Collaboration () equation of less than 50 mL/min/1.73m2.
  1. Known or current history of pneumonitis or interstitial lung disease (e.g., idiopathic pulmonary fibrosis) or pneumonia in past month 8. Has known or active (e.g., HBV detected by PCR, presence of HBsAg surface antigen and/or Anti-HBc core antigen) or active (e.g., HCV RNA [qualitative] is detected). Presence of Anti-HBs alone suggesting immunity to Hepatis B is eligible.
  1. Any serious known immediate or delayed reaction(s) to dupilumab and or cemiplimab.
  1. Concurrent medical condition requiring the use of systemic medications, or systemic at doses of greater than 10 mg Prednisone-equivalent. Topical steroids and other localized corticosteroids are permitted. Patients who have received acute, low-dose, systemic immunosuppressant medications equivalent to ≤ 10mg of prednisone within the 7 days prior to study entry (small dose of dexamethasone for nausea, short course for upper respiratory tract infection etc.) may be enrolled in the study. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.
  1. Concurrent use or planned use of any forbidden medications within 4 weeks prior to study drug administration, which include chemotherapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control cancers), other biologic therapy, therapy, or hormonal therapy.
  1. Confirmed pregnancy (by pregnancy test) if patient is of childbearing age or breast feeding.
  1. Subjects with signs/symptoms suggestive of COVID-19 and confirmed positive COVID-19 test.
  1. (ECOG) performance status ≥3 (see Appendix) 15. Any underlying medical condition that, in the Principal Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events, or renders the patient ineligible to be on study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Arm A: Cemiplimab

    Arm A: Cemiplimab (n=10), 350mg IV x 1 dose administered prior to surgery.

    Drug: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab

  • Experimental
    Arm B: Cemiplimab + Dupilumab

    Arm B: Cemiplimab + Dupilumab (n=10), Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery.

    Drug: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab

Interventions

  • DrugArm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab

    Drug pages: CemiplimabStudies of CemiplimabCemiplimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery

06

What researchers measure

Primary outcomes

  1. Immune Cell Population Analysis

    The % change in various immune cell populations (CD3, CD8, macrophages and DC cells) in the tumor and microenvironment, Defined as the post-treatment value / pre-treatment value \* 100%

    Time frame: up to 6 months

Secondary outcomes

  1. Study Participant Assessment of Adverse Effects

    Number of participants with treatment-related adverse effects of patients treated with short term cemiplimab + dupilumab, using NCI-CTCAE

    Time frame: up to 6 months

Other outcomes

  1. PD-1 Gene Expression

    PD-1 Gene expression analysis in pre treatment tissue samples expression and its effect on the immune response in treated and untreated patients

    Time frame: up to 6 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Aug 2024, 11 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 11 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Aug 1, 2023
StartEst.
Aug 4, 2023
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967884
Collaborators
Ontario Institute for Cancer Research
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 4, 2023 (estimated)
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2024 (estimated)
Last update
Aug 1, 2023

Study contacts

Angel Arnaout, MD
Contact
anarnaout@toh.ca
613-798-5555

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cemiplimab · Dupilumab

Start the discussion